3,573 results on '"GASBARRINI, G."'
Search Results
202. IgE TO FOOD ALLERGENS AND GASTROINTESTINAL SYMPTOMS IN BIRCH AND/OR OLIVE TREE POLLEN ALLERGIC PATIENTS : 360
- Author
-
Ricciuto, G., Marsigli, L., Emiliani, F., Romano, A., Gasbarrini, G., and Stefanini, G.
- Published
- 1997
203. Immediate hypersensitivity to penicillins. Studies on Italian subjects
- Author
-
Romano, A., Blanca, M., Mayorga, C., Venuti, A., and Gasbarrini, G.
- Published
- 1997
204. COVID-19 in celiac disease: a multicentric retrospective cohort study.
- Author
-
GASBARRINI, G., DIONISI, T., CORAZZA, G. R., ARONICO, N., CAMMAROTA, G., IANIRO, G., DE VITIS, I., CANDELLI, M., MANCARELLA, F. A., SIMEONI, S., ADDOLORATO, G., and BONVICINI, F.
- Abstract
OBJECTIVE: Celiac disease (CD) is an autoimmune disorder, characterized by increased susceptibility to bacterial and viral infections. Therefore, the CD patients could be exposed to an increased risk of contracting SARSCoV-2, a virus for which the WHO declared a pandemic status in March 2020. This study aims to investigate the incidence of SARS-CoV-2 infection in CD patients, to assess the impact of CD on the risk of contracting this virus. PATIENTS AND METHODS: This retrospective multicentric cohort study evaluated 542 celiac patients, who answered a questionnaire concerning both the underlying disease (adherence to the gluten-free diet, residual symptoms) and the possible SARS-CoV-2 infection (swab outcome, presence and characteristics of symptoms and type of treatment received), referring to the period between 20th January 2020 and 27th October 2020. RESULTS: Five patients (0.92%) tested positive; of these, 2 were asymptomatic and 3 developed symptoms of COVID-19. The incidence of SARSCoV-2 infection in CD patients was not significantly different from the general population. The ratio of positive/diagnostic swabs tends to be higher in CD patients than in the general population (IR: 0.15; 0.06; p=0.06), whereas the number of subjects who performed the swab in this group is significantly lower (IR: 0.06; 0.15; p<0.001). CONCLUSIONS: Although CD patients are more susceptible to infections, the incidence of SARS-CoV-2 infection in our sample was not significantly different from the general population. However, the positive/diagnostic swabs ratio seems to be higher, probably also due to the lower number of patients tested. [ABSTRACT FROM AUTHOR]
- Published
- 2021
205. Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin
- Author
-
CAMMAROTA, G., TURSI, A., PAPA, A., MONTALTO, M., VENETO, G., CUOCO, L., FEDELI, G., and GASBARRINI, G.
- Published
- 1996
206. Authors' reply: Familial hyperchylomicronaemia
- Author
-
Gasbarrini, G., Mingrone, G., Greco, A. V., and Castagneto, M.
- Published
- 1996
207. Doppler ultrasonographic evaluation of splanchnic blood flow in coeliac disease
- Author
-
Arienti, V., Califano, C., Brusco, G., Boriani, L., Biagi, F., Giulia Sama, M., Sottili, S., Domanico, A., Corazza, G. R., and Gasbarrini, G.
- Published
- 1996
208. Nonmigrainous Headache from Food Allergy
- Author
-
STEFANINI, G. F., MARSIGLI, L., FOSCHI, F. G., EMILIANI, F., BISELLI, M., CAPUTO, F., LEEFIELD, G. H., CASTELLI, E., and GASBARRINI, G.
- Published
- 1996
209. Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection
- Author
-
TURSI, A., CAMMAROTA, G., MONTALTO, M., PAPA, A., VENETO, G., CUOCO, L., TRUA, F., BRANCA, G., FEDELI, G., and GASBARRINI, G.
- Published
- 1996
210. Association of Helicobacter pylori infection, lymphoid follicles, and lymphocytic gastritis: a risk factor for the development of primary gastric lymphoma?
- Author
-
Cammarota, G., Tursi, A., Fedeli, G., and Gasbarrini, G.
- Published
- 1996
211. Coeliac disease and follicular gastritis
- Author
-
Cammarota, G., Fedeli, G., Tursi, A., Corazza, G. R., and Gasbarrini, G.
- Published
- 1996
212. C13/218 PROTEIN OXIDATION IN RAT FATTY LIVER EXPOSED TO HYPOXIA-REOXYGENATION
- Author
-
Colantoni, A., De Maria, N., Fagiuoli, S., Gasbarrini, A., Caraceni, P., Gasbarrini, G., Van Thiel, D. H., and Bernardi, M.
- Published
- 1996
213. ALLERGIC REACTIONS TO PENICILLINS: STUDIES IN AN ITALIAN POPULATION: PD 211
- Author
-
Quarantino, D., Blanca, M., Romano, A., Mayorga, C., Di Fonso, M., Venuti, A., and Gasbarrini, G. B.
- Published
- 1996
214. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report
- Author
-
Malfertheiner, P., Megraud, F., O'Morain, C. A., Gisbert, J. P., Kuipers, E. J., Axon, A. T., Bazzoli, F., Gasbarrini, A., Atherton, J., Graham, D. Y., Hunt, R., Moayyedi, P., Rokkas, T., Rugge, M., Selgrad, M., Suerbaum, S., Sugano, K., El-Omar, E. M., Agreus, L., Andersen, L. P., Axon, A., Coelho, L., Delchier, J. C., Di Mario, F., Dinis-Ribeiro, M., El-Omar, E., Fischbach, W., Flahou, B., Fock, K. M., Gasbarrini, G., Gensini, G., Gisbert, J., Goh, K. L., Herrero, R., Kupcinskas, L., Lanas, A., Leja, M., Machado, J. C., Mahachai, V., Milosavljevic, T., Molina-Infante, J., Niv, Y., O'Morain, C., Ristimaki, A., Tepes, B., Vaira, D., Vieth, M., You, W., Gastroenterology & Hepatology, Malfertheiner, P., Megraud, F., O'Morain, C.A., Gisbert, J.P., Kuipers, E.J., Axon, A.T., Bazzoli, F., Gasbarrini, A., Atherton, J., Graham, D.Y., Hunt, R., Moayyedi, P., Rokkas, T., Rugge, M., Selgrad, M., Suerbaum, S., Sugano, K., El-Omar, E.M., Agreus, L., Andersen, L.P., Axon, A., Coelho, L., Delchier, J.C., Di Mario, F., Dinis-Ribeiro, M., El-Omar, E., Fischbach, W., Flahou, B., Fock, K.M., Gasbarrini, G., Gensini, G., Gisbert, J., Goh, K.L., Herrero, R., Kupcinskas, L., Lanas, A., Leja, M., Machado, J.C., Mahachai, V., Milosavljevic, T., Molina-Infante, J., Niv, Y., O'Morain, C., Ristimaki, A., Tepes, B., Vaira, D., Vieth, M., and You, W.
- Subjects
Helicobacter pylori infection ,Proton Pump Inhibitor ,Gastroenterology ,0302 clinical medicine ,Fluoroquinolone ,Risk Factors ,HELICOBACTER THERAPY ,Medicine ,Early Detection of Cancer ,Evidence-Based Medicine ,biology ,Microbial Sensitivity Test ,Stomach ,Consensus conference ,Anti-Bacterial Agents ,Nitroimidazoles ,030220 oncology & carcinogenesis ,Practice Guidelines as Topic ,030211 gastroenterology & hepatology ,Drug Therapy, Combination ,Fluoroquinolones ,Human ,medicine.medical_specialty ,Settore MED/12 - GASTROENTEROLOGIA ,Microbial Sensitivity Tests ,Helicobacter Infections ,03 medical and health sciences ,Stomach Neoplasms ,Stomach Neoplasm ,Internal medicine ,Clarithromycin ,Clarithromycin resistance ,Anti-Bacterial Agent ,Drug Resistance, Bacterial ,Gastroscopy ,Humans ,Dyspepsia ,GASTRITIS ,HELICOBACTER PYLORI ,Helicobacter pylori ,business.industry ,Public health ,Nitroimidazole ,Risk Factor ,Gastriti ,Amoxicillin ,Proton Pump Inhibitors ,biology.organism_classification ,Gastrointestinal Microbiome ,Family medicine ,business ,Bismuth ,Helicobacter Infection - Abstract
Important progress has been made in the management of Helicobacter pylori infection and in this fifth edition of the Maastricht Consensus Report, key aspects related to the clinical role of H. Pylori were re-evaluated in 2015. In the Maastricht V/Florence Consensus Conference, 43 experts from 24 countries examined new data related to H. pylori in five subdivided workshops: (1) Indications/ Associations, (2) Diagnosis, (3) Treatment, (4) Prevention/Public Health, (5) H. pylori and the Gastric Microbiota. The results of the individual workshops were presented to a final consensus voting that included all participants. Recommendations are provided on the basis of the best available evidence and relevance to the management of H. pylori infection in the various clinical scenarios.
- Published
- 2017
215. Microbes and Alzheimer' disease: Lessons from H. Pylori and GUT microbiota
- Author
-
Franceschi, Francesco, Ojetti, Veronica, Candelli, Marcello, Covino, Marcello, Cardone, S., Potenza, Angelo Eugenio, Simeoni, Benedetta, Gabrielli, Maurizio, Sabia, Luca, Gasbarrini, Giovanni Battista, Lopetuso, Loris Riccardo, Scaldaferri, Franco, Rossini, Paolo Maria, Gasbarrini, Antonio, Franceschi, F. (ORCID:0000-0001-6266-445X), Ojetti, V. (ORCID:0000-0002-8953-0707), Candelli, M. (ORCID:0000-0001-8443-7880), Covino, M. (ORCID:0000-0002-6709-2531), Simeoni, B., Gabrielli, M., Gasbarrini, G., Lopetuso, L., Scaldaferri, F. (ORCID:0000-0001-8334-7541), Rossini, P. M. (ORCID:0000-0003-2665-534X), Gasbarrini, A. (ORCID:0000-0002-7278-4823), Franceschi, Francesco, Ojetti, Veronica, Candelli, Marcello, Covino, Marcello, Cardone, S., Potenza, Angelo Eugenio, Simeoni, Benedetta, Gabrielli, Maurizio, Sabia, Luca, Gasbarrini, Giovanni Battista, Lopetuso, Loris Riccardo, Scaldaferri, Franco, Rossini, Paolo Maria, Gasbarrini, Antonio, Franceschi, F. (ORCID:0000-0001-6266-445X), Ojetti, V. (ORCID:0000-0002-8953-0707), Candelli, M. (ORCID:0000-0001-8443-7880), Covino, M. (ORCID:0000-0002-6709-2531), Simeoni, B., Gabrielli, M., Gasbarrini, G., Lopetuso, L., Scaldaferri, F. (ORCID:0000-0001-8334-7541), Rossini, P. M. (ORCID:0000-0003-2665-534X), and Gasbarrini, A. (ORCID:0000-0002-7278-4823)
- Abstract
OBJECTIVE: the role of microbes and chronic inflammation in the pathogenesis of Alzheimer' disease (AD) has been postulated by many authors. On the other hand, several studies have reported the main role of H. pylori infection and/or GUT microbiota alteration in promoting chronic inflammation, thus possibly influencing both occurrence and evolution of AD. In this article, we analyze the most important and recent studies performed on this field both on humans and animals and provide possible pathogenic explanations. RESULTS: all main and most recent animal, human, epidemiological and in-silico studies, showed a role of H. pylori and/or dysbiosis in AD, mostly through the promotion of systemic chronic inflammation and/or by triggering molecular mimicry mechanisms. In particular, H. pylori infection seems to be related to a poorer cognitive performance. CONCLUSIONS: Indeed, bacteria have been shown to affect neurodegeneration by promoting inflammation, inducing molecular mimicry mechanisms and accumulation of Aß into the brain. These findings open the way for H. pylori eradicating trials and/or GUT microbiota remodulating strategies. Therefore, further studies are now needed in order to test whether antibiotics, pre and/or probiotics may exert a beneficial effect in the prevention of AD.
- Published
- 2019
216. Endothelin-1 in idiopathic pulmonary fibrosis
- Author
-
Uguccioni, M., Pulsatelli, L., Grigolo, B., Facchini, A., Fasano, L., Cinti, C., Fabbri, M., Gasbarrini, G., and Meliconi, R.
- Published
- 1995
217. Helicobacter pylori reinfection and rapid relapse of low-grade B-cell gastric lymphoma
- Author
-
Cammarota, G, Montalto, M, Tursi, A, Vecchio, F M, Fedeli, G, and Gasbarrini, G
- Published
- 1995
218. Gut microbiota in autism and mood disorders
- Author
-
Mangiola, F, Ianiro, G, Franceschi, F, Fagiuoli, S, Gasbarrini, G, Gasbarrini, A, Mangiola F., Ianiro G., Franceschi F., Fagiuoli S., Gasbarrini G., Gasbarrini A., Mangiola, F, Ianiro, G, Franceschi, F, Fagiuoli, S, Gasbarrini, G, Gasbarrini, A, Mangiola F., Ianiro G., Franceschi F., Fagiuoli S., Gasbarrini G., and Gasbarrini A.
- Abstract
The hypothesis of an important role of gut microbiota in the maintenance of physiological state into the gastrointestinal (GI) system is supported by several studies that have shown a qualitative and quantitative alteration of the intestinal flora in a number of gastrointestinal and extra-gastrointestinal diseases. In the last few years, the importance of gut microbiota impairment in the etiopathogenesis of pathology such as autism, dementia and mood disorder, has been raised. The evidence of the inflammatory state alteration, highlighted in disorders such as schizophrenia, major depressive disorder and bipolar disorder, strongly recalls the microbiota alteration, highly suggesting an important role of the alteration of GI system also in neuropsychiatric disorders. Up to now, available evidences display that the impairment of gut microbiota plays a key role in the development of autism and mood disorders. The application of therapeutic modulators of gut microbiota to autism and mood disorders has been experienced only in experimental settings to date, with few but promising results. A deeper assessment of the role of gut microbiota in the development of autism spectrum disorder (ASD), as well as the advancement of the therapeutic armamentarium for the modulation of gut microbiota is warranted for a better management of ASD and mood disorders.
- Published
- 2016
219. Helicobacter pylori is an aetiological factor for ischaemic heart disease: the case against
- Author
-
Cammarota, G., Pasceri, V., Gasbarrini, A., and Gasbarrini, G.
- Published
- 2000
- Full Text
- View/download PDF
220. Clinical nutrition practice in Italian Gastroenterology Units
- Author
-
Guglielmi, F.W., Panella, C., Losco, A., Budillon, G., Conte, D., Del Vecchio Blanco, C., Gasbarrini, G., Loguercio, C., Merli, M., Mingrone, G., Nardone, G., Riggio, O., and Francavilla, A.
- Published
- 2000
- Full Text
- View/download PDF
221. Insulin resistance directly correlates with increased saturated fatty acids in skeletal muscle triglycerides
- Author
-
Manco, M., Greco, A.V., Capristo, E., Gniuli, D., De Gaetano, A., and Gasbarrini, G.
- Published
- 2000
- Full Text
- View/download PDF
222. Body composition changes induced by chronic ethanol abuse: evaluation by dual energy x-ray absorptiometry
- Author
-
Addolorato, G, Capristo, E, Marini, M, Santini, P, Scognamiglio, U, Attilia, M.L, Messineo, D, Sasso, G.F, Gasbarrini, G, and Ceccanti, M
- Published
- 2000
- Full Text
- View/download PDF
223. Return Of Splenic Function After Splenectomy: How Much Tissue Is Needed?
- Author
-
Corazza, G. R., Tarozzi, C., Vaira, D., Frisoni, M., and Gasbarrini, G.
- Published
- 1984
224. Investigation Of QT Interval In Adult Coeliac Disease
- Author
-
Corazza, G. R., Frisoni, M., Filipponi, C., Gullo, L., Poggi, V. M., and Gasbarrini, G.
- Published
- 1992
225. Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study
- Author
-
BISELLI M, ANDREONE P, GRAMENZI A, TREVISANI F, CURSARO C, ROSSI C, RICCA, ROSELLINI S, CAMMA', Calogero, LORENZINI S, STEFANINI GF, GASBARRINI G, BERNARDI M., Biselli M., Andreone P., Gramenzi A., Trevisani F., Cursaro C., Rossi C., Ricca-Rossellini S., Cammà C., Lorenzini S., Stefanini G.F., Gasbarrini G., Bernardi M., BISELLI M, ANDREONE P, GRAMENZI A, TREVISANI F, CURSARO C, ROSSI C, RICCA, ROSELLINI S, CAMMA' C, LORENZINI S, STEFANINI GF, GASBARRINI G, and BERNARDI M
- Subjects
Liver Cirrhosis ,Male ,Cirrhosis ,Time Factors ,Prognostic system ,Gastroenterology ,Oily chemoembolization ,Hepatic Artery ,Cause of Death ,Ascites ,Validation ,Medicine ,Stage (cooking) ,CIRRHOSIS ,Univariate analysis ,Antibiotics, Antineoplastic ,Liver Neoplasms ,Liver-Transplantation ,Middle Aged ,HEPATOCELLULAR CARCINOMA ,TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION ,SURVIVAL ,SIDE EFFECTS ,Prognosis ,Treatment Outcome ,Italy ,Randomized controlled trial ,Hepatocellular carcinoma ,Female ,medicine.symptom ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Multivariate-analysi ,Transarterial chemoembolization ,Internal medicine ,Carcinoma ,Humans ,Chemoembolization, Therapeutic ,Transcatheter arterial chemoembolization ,Survival analysis ,Aged ,Epirubicin ,Neoplasm Staging ,Cirrhosi ,Hepatology ,business.industry ,medicine.disease ,Survival Analysis ,Surgery ,Lipiodol chemoembolization ,Case-Control Studies ,Multivariate Analysis ,business ,Follow-Up Studies - Abstract
Background & Aims: Transcatheter arterial chemoembolization (TACE) currently is used as a palliative treatment for patients with unresectable hepatocellular carcinoma (HCC), but its efficacy still is debated. Our aim was to assess the impact of TACE on patient survival and to identify prognostic factors for survival. Methods: Fifty-six cirrhotic patients with unresectable HCC undergoing at least :1 course of TACE were matched 1:1. for sex, age (in 5-year periods), parameters of Child-Pugh score, Okuda stage, and tumor type with a control group who had received only supportive care. Results: The 2 groups were comparable for cause of cirrhosis, alpha-fetoprotein serum levels, and Cancer of the Liver Italian Program (CLIP) score. The 56 patients in the TACE group received a total of 123 treatment courses. The median follow-up period was 16 months (range, 1-67 mo) in the TACE group and 5 months (range, 1-77 mo) in the supportive care group. Survival rates at 12, 24, and 30 months in patients receiving TACE were 74.3%, 52.1%, and 38.8% respectively, with a median survival time of 25 month whereas in supportive care patients the rates we 39.4%, 25.4%, and 19%, respectively, with a median survival time of 7 months (P =.0004). At univariate analysis, TACE, tumor type, presence of ascites, alpha-fetoprotein serum level, CLIP score, and Okuda stage were associated significantly with survival. Only TACE and CLIP score proved to be independent predictors of survival at multivariate analysis. Conclusions: TACE is an effective therapeutic option for cirrhotic patients with unresectable HCC and a CLIP score of 3 or less.
- Published
- 2005
226. Liver transplantation in alcoholic patients: Impact of an alcohol addiction unit within a liver transplant center
- Author
-
Addolorato, G., Mirijello, A., Leggio, L., Ferrulli, A., D'Angelo, C., Vassallo, G., Cossari, A., Gasbarrini, G., Landolfi, R., Agnes, S., Gasbarrini, A., Abbate, V., Abenavoli, L., Antonelli, M., Annicchiarico, E., Avolio, A. W., Biolato, M., Campanale, C., Capristo, E., Caputo, F., Cesario, V., Castagneto, M., Dematthaeis, N., Favale, C., Ferrarese, D., Garcovich, M., Frongillo, F., Grieco, A., Malandrino, N., Miele, L., Milani, A., Nesci, A., Nure, E., Pelecca, G., Pepe, G., Pietrogiacomi, P., Pizzolante, F., Pompili, M., Romana Ponziani, F., Rapaccini, G., Riccardi, L., Rinninella, E., Santoro, M. C., Sganga, G., Siciliano, M., Vero, V., Vonghia, L., Addolorato G. (ORCID:0000-0002-1522-9946), Mirijello A., D'Angelo C., Gasbarrini G., Landolfi R. (ORCID:0000-0002-7913-8576), Agnes S. (ORCID:0000-0002-3341-4221), Gasbarrini A. (ORCID:0000-0002-7278-4823), Antonelli M. (ORCID:0000-0003-3007-1670), Annicchiarico E., Avolio A. W. (ORCID:0000-0003-2491-7625), Capristo E. (ORCID:0000-0002-5753-3495), Caputo F., Cesario V., Frongillo F., Grieco A. (ORCID:0000-0002-0544-8993), Miele L. (ORCID:0000-0003-3464-0068), Milani A. (ORCID:0000-0003-1303-7737), Nesci A. (ORCID:0000-0001-9466-1755), Nure E., Pizzolante F., Pompili M. (ORCID:0000-0001-6699-7980), Rapaccini G. (ORCID:0000-0002-6467-857X), Riccardi L., Rinninella E. (ORCID:0000-0002-9165-2367), Sganga G. (ORCID:0000-0001-5079-0395), Siciliano M., Vero V., Vonghia L., Addolorato, G., Mirijello, A., Leggio, L., Ferrulli, A., D'Angelo, C., Vassallo, G., Cossari, A., Gasbarrini, G., Landolfi, R., Agnes, S., Gasbarrini, A., Abbate, V., Abenavoli, L., Antonelli, M., Annicchiarico, E., Avolio, A. W., Biolato, M., Campanale, C., Capristo, E., Caputo, F., Cesario, V., Castagneto, M., Dematthaeis, N., Favale, C., Ferrarese, D., Garcovich, M., Frongillo, F., Grieco, A., Malandrino, N., Miele, L., Milani, A., Nesci, A., Nure, E., Pelecca, G., Pepe, G., Pietrogiacomi, P., Pizzolante, F., Pompili, M., Romana Ponziani, F., Rapaccini, G., Riccardi, L., Rinninella, E., Santoro, M. C., Sganga, G., Siciliano, M., Vero, V., Vonghia, L., Addolorato G. (ORCID:0000-0002-1522-9946), Mirijello A., D'Angelo C., Gasbarrini G., Landolfi R. (ORCID:0000-0002-7913-8576), Agnes S. (ORCID:0000-0002-3341-4221), Gasbarrini A. (ORCID:0000-0002-7278-4823), Antonelli M. (ORCID:0000-0003-3007-1670), Annicchiarico E., Avolio A. W. (ORCID:0000-0003-2491-7625), Capristo E. (ORCID:0000-0002-5753-3495), Caputo F., Cesario V., Frongillo F., Grieco A. (ORCID:0000-0002-0544-8993), Miele L. (ORCID:0000-0003-3464-0068), Milani A. (ORCID:0000-0003-1303-7737), Nesci A. (ORCID:0000-0001-9466-1755), Nure E., Pizzolante F., Pompili M. (ORCID:0000-0001-6699-7980), Rapaccini G. (ORCID:0000-0002-6467-857X), Riccardi L., Rinninella E. (ORCID:0000-0002-9165-2367), Sganga G. (ORCID:0000-0001-5079-0395), Siciliano M., Vero V., and Vonghia L.
- Abstract
Background: Many concerns about liver transplantation in alcoholic patients are related to the risk of alcohol recidivism. Starting from 2002, an Alcohol Addiction Unit (AAU) was formed within the liver transplant center for the management of alcoholic patients affected by end-stage liver disease and included in the waiting list for transplantation. We evaluated retrospectively the impact of the AAU on alcohol recidivism after transplantation. The relationship between alcohol recidivism and the duration of alcohol abstinence before transplant was evaluated as well. Methods: Between 1995 and 2010, 92 cirrhotic alcoholic patients underwent liver transplantation. Clinical evaluation and management of alcohol use in these patients was provided by psychiatrists with expertise in addiction medicine not affiliated to the liver transplant center before 2002 (n = 37; group A), or by the clinical staff of the AAU within the liver transplant center starting from 2002 (n = 55; group B). Results: Group B, as compared with group A, showed a significantly lower prevalence of alcohol recidivism (16.4 vs. 35.1%; p = 0.038) and a significantly lower mortality (14.5 vs. 37.8%; p = 0.01). Furthermore, an analysis of group B patients with either ≥6 or <6 months of alcohol abstinence before transplantation showed no difference in the rate of alcohol recidivism (21.1 vs. 15.4%; p = ns). Conclusions: The presence of an AAU within a liver transplant center reduces the risk of alcohol recidivism after transplantation. A pretransplant abstinence period <6 months might be considered, at least in selected patients managed by an AAU. © 2013 by the Research Society on Alcoholism.
- Published
- 2013
227. Low risk of colon cancer in patients with celiac disease
- Author
-
Volta, Umberto, Vincentini, Olimpia, Quintarelli, Federica, Felli, Cristina, Silano, Marco, Gasbarrini, G, De Vitis, V, Santini, D, Scaggiante, F, Castellano, E, Grosso, S, Campanella, J, Corazza, GR, Sandri, G, Giorgetti, G, Caio, G, Lo Perfido, S, Perri F, Festa V, Pelli MA, Cavalletti ML, Segato S, Curzio M, Pennazio M, Rossini FP, Picarelli A, Pera A, Ercole E, Passaleva MT, Barbato M, Usai P, Dore MF, Chilovi F, Piazzi L, Zancanella L, Boarino V, Ferrari A., GRECO, LUIGI, AURICCHIO, SALVATORE, Volta, Umberto, Vincentini, Olimpia, Quintarelli, Federica, Felli, Cristina, Silano, Marco, Gasbarrini, G, De Vitis, V, Greco, Luigi, Auricchio, Salvatore, Santini, D, Scaggiante, F, Castellano, E, Grosso, S, Campanella, J, Corazza, Gr, Sandri, G, Giorgetti, G, Caio, G, Lo, Perfido, S, Perri, F, Festa, V, Pelli, Ma, Cavalletti, Ml, Segato, S, Curzio, M, Pennazio, M, Rossini, Fp, Picarelli, A, Pera, A, Ercole, E, Passaleva, Mt, Barbato, M, Usai, P, Dore, Mf, Chilovi, F, Piazzi, L, Zancanella, L, Boarino, V, Ferrari, A., Volta U, Vincentini O, Quintarelli F, Felli C, Silano M, and Collaborating Centres of the Italian Registry of the Complications of Celiac Disease
- Subjects
Male ,Colorectal cancer ,COLON CANCER ,Disease ,Gastroenterology ,Colon carcinoma ,Retrospective Studie ,Medicine ,Child ,Colonic Neoplasm ,education.field_of_study ,Medicine (all) ,Incidence ,Celiac disease ,Gluten-free diet ,Adolescent ,Adult ,Carcinoma ,Celiac Disease ,Child, Preschool ,Colonic Neoplasms ,Diet, Gluten-Free ,Female ,Follow-Up Studies ,Humans ,Infant ,Infant, Newborn ,Italy ,Middle Aged ,Patient Compliance ,Retrospective Studies ,Risk Assessment ,Young Adult ,Population study ,Human ,Cohort study ,medicine.medical_specialty ,Population ,Follow-Up Studie ,NO ,Internal medicine ,In patient ,Preschool ,education ,business.industry ,Newborn ,medicine.disease ,digestive system diseases ,Diet ,Standardized mortality ratio ,Gluten-Free ,Celiac disease, colon carcinoma, gluten-free diet ,business - Abstract
Objective. Celiac disease (CD) has strongly been established as associated with some site-specific gastrointestinal malignancies. On the contrary, according to the few reports available, the risk of colon carcinoma in CD patients has been described similar to that of general population. In this cohort study, we describe the risk of colon carcinoma in a group of Italian celiac patients. Materials and methods. The study population included all CD patients diagnosed at the Collaborating Centers of the Italian Registry of CD between 1st January 1982 and 31st December 2006. Upon diagnosis of CD and upon at every subsequent clinical control, the Collaborating Centers filled in a validated form for each CD patient reporting information about demographic data, possible occurrence of a neoplasm and adherence to a gluten-free diet. Results. Out of 1757 celiac patients enrolled, 6 developed a colon carcinoma during the follow-up period (mean: 18.1 years). The standardized incidence ratio (SIR) resulted 0.29 (95% CI = 0.07–0.45). Stratifying the risk for the dietary gluten intake, the SIR dropped to 0.07 (95% CI = 0.009–0.27) for CD patients with a strict adherence to a gluten-free diet. Conclusion. We confirm the previous finding that there is low risk to develop a colon cancer in celiac patients.
- Published
- 2014
228. P.02.13: Can Gender Affect Dob Values Obtained by 13-C Urea Breath Test?
- Author
-
Petruzziello, C., primary, Tesori, V., additional, Graziani, C., additional, Gabrielli, M., additional, Candelli, M., additional, Gasbarrini, G., additional, Gasbarrini, A., additional, Franceschi, F., additional, and Ojetti, V., additional
- Published
- 2017
- Full Text
- View/download PDF
229. The rational use of albumin in patients with cirrhosis and ascites. A Delphi study for the attainment of a consensus on prescribing standards
- Author
-
GENTILINI P, BERNARDI M, BOLONDI L, CRAXI, Antonio, GASBARRINI G, IDEO G, LAFFI, G, LA VILLA G, SALERNO F, VENTURA E, PULAZZINI A, SEGANTINI L, ROMANELLI RG, GENTILINI P., BERNARDI M., BOLONDI L., CRAXI A., GASBARRINI G., IDEO G., LAFFI G., LA VILLA G., SALERNO F., VENTURA E., PULAZZINI A., SEGANTINI L., ROMANELLI R.G., GENTILINI P, BERNARDI M, BOLONDI L, CRAXI' A, GASBARRINI G, IDEO G, LAFFI, LA VILLA G, SALERNO F, VENTURA E, PULAZZINI A, SEGANTINI L, and ROMANELLI RG
- Subjects
ascite ,DELPHI METHOD ,ALBUMIN ,ASCITES ,CIRRHOSIS ,cirrhosi - Abstract
Background. Ascites is one of the most frequent severe complications in patients with liver cirrhosis. The treatment of this chronic disease usually requires the prolonged use of albumin, frequently continued even after patients' discharge from the hospital. Aims. Aim of the study was to define a consensus among Italian physicians with regard to the use of albumin in patients with decompensated cirrhosis and ascites. Methods. The study adopted the Delphi technique to conduct the consensus activities. All controversial issues related to the use of albumin were identified by the experts' board and proposed to the 68 participating hepatology centres through two subsequent questionnaires. The questionnaires, returned by the specialists involved, were collected and the answers classified to verify the elements on which a consensus was reached. Results. The home use of albumin can help to improve the patient's general conditions and well-being. About 77% of the experts involved considered likely that albumin administration could shorten hospital stays or could reduce the number of hospital admissions. The results of the study, along with a socioeconomic analysis, were presented to the Italian Drug Commission, which subsequently removed the specific hypoalbuminemia level as a prerequisite for having the drug reimbursed by the National Health Service. Conclusions. For an outpatient prescription, the hypoalbuminemia limit of 2.5 g/dl or less is not sufficient, while the decision whether to administer the drug requires the evaluation of patient's overall clinical conditions as an essential criterion for the prescription of a home treatment with albumin.
- Published
- 2004
230. In vitro Lymphocytotoxicity in Intrahepatic Cholestasis1
- Author
-
A. Facchini, E. Mariani, Bernardi M, F. Miglio, Gasbarrini G, G. F. Stefanini, and Giuseppe Labò
- Subjects
Chemistry ,Cancer research ,In vitro - Published
- 2015
- Full Text
- View/download PDF
231. Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins?
- Author
-
Biolato, Marco, Marrone, Giuseppe, Racco, Simona, Di Stasi, Carmine, Miele, Luca, Gasbarrini, G, Landolfi, Raffaele, Grieco, Antonio, Di Stasi, Carmine (ORCID:0000-0002-6822-3599), Miele, Luca (ORCID:0000-0003-3464-0068), Gasbarrini G, Landolfi, Raffaele (ORCID:0000-0002-7913-8576), Grieco, Antonio (ORCID:0000-0002-0544-8993), Biolato, Marco, Marrone, Giuseppe, Racco, Simona, Di Stasi, Carmine, Miele, Luca, Gasbarrini, G, Landolfi, Raffaele, Grieco, Antonio, Di Stasi, Carmine (ORCID:0000-0002-6822-3599), Miele, Luca (ORCID:0000-0003-3464-0068), Gasbarrini G, Landolfi, Raffaele (ORCID:0000-0002-7913-8576), and Grieco, Antonio (ORCID:0000-0002-0544-8993)
- Abstract
BACKGROUND AND OBJECTIVES: To provide an overview on the loco-regional therapy performed by transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC), either as sole, either as neoadjuvant to surgery or bridge therapy to orthotopic liver transplantation (OLT). EVIDENCE AND INFORMATION SOURCES: The current review is based on an analysis of the current literature and the caseload experience of the Authors on this topic. STATE OF THE ART: Chemoembolization combines de-arterialization of the tumor and selective delivery of chemotherapeutic agents into tumor's feeding vessels during angiography. Tumor ischemia raises the drug concentration compared to infusion alone and extends the retention of the chemotherapeutic drug. As locoregional therapy, TACE allows a complete local tumor control of 25-35% and permits an increase of survival in patients with intermediate HCC according to Barcelona-Clinic Liver Cancer (BCLC) classification. Excellent results were also achieved by combined therapies, such as with percutaneous ethanol injection or radiofrequency ablation, as neoadjuvant therapy prior to liver resection and in some circumstances as a bridging tool before liver transplantation. PERSPECTIVES: Drug eluting beads are microspheres that can be loaded with doxorubicin and induce toxic and ischemic necrosis with the same device; that allows an increase of drug selectively exposed to tumor cells and simultaneously a reduction of systemic toxicity. Tumor embolization induces a neoangiogenic reaction with a significant growth of adiacent satellites, so the association with sorafenib has a strong rationale for a combined therapy and is currently under investigation. CONCLUSIONS: Today TACE is the standard of care for treatment of intermediate hepatocellular carcinoma. To get the best performance it should be tailored according to the individual patient's condition.
- Published
- 2010
232. European consensus conference on faecal microbiota transplantation in clinical practice
- Author
-
Cammarota, G, Ianiro, G, Tilg, H, Rajilic-Stojanovic, M, Kump, P, Satokari, R, Sokol, H, Arkkila, P, Pintus, C, Hart, A, Segal, J, Aloi, M, Masucci, L, Molinaro, A, Scaldaferri, F, Gasbarrini, G, Lopez-Sanroman, A, Link, A, De Groot, P, de Vos, WM, Hoegenauer, C, Malfertheiner, P, Mattila, E, Milosavljevic, T, Nieuwdorp, M, Sanguinetti, M, Simren, M, Gasbarrini, A, Cammarota, G, Ianiro, G, Tilg, H, Rajilic-Stojanovic, M, Kump, P, Satokari, R, Sokol, H, Arkkila, P, Pintus, C, Hart, A, Segal, J, Aloi, M, Masucci, L, Molinaro, A, Scaldaferri, F, Gasbarrini, G, Lopez-Sanroman, A, Link, A, De Groot, P, de Vos, WM, Hoegenauer, C, Malfertheiner, P, Mattila, E, Milosavljevic, T, Nieuwdorp, M, Sanguinetti, M, Simren, M, and Gasbarrini, A
- Abstract
Faecal microbiota transplantation (FMT) is an important therapeutic option for Clostridium difficile infection. Promising findings suggest that FMT may play a role also in the management of other disorders associated with the alteration of gut microbiota. Although the health community is assessing FMT with renewed interest and patients are becoming more aware, there are technical and logistical issues in establishing such a non-standardised treatment into the clinical practice with safety and proper governance. In view of this, an evidence-based recommendation is needed to drive the practical implementation of FMT. In this European Consensus Conference, 28 experts from 10 countries collaborated, in separate working groups and through an evidence-based process, to provide statements on the following key issues: FMT indications; donor selection; preparation of faecal material; clinical management and faecal delivery and basic requirements for implementing an FMT centre. Statements developed by each working group were evaluated and voted by all members, first through an electronic Delphi process, and then in a plenary consensus conference. The recommendations were released according to best available evidence, in order to act as guidance for physicians who plan to implement FMT, aiming at supporting the broad availability of the procedure, discussing other issues relevant to FMT and promoting future clinical research in the area of gut microbiota manipulation. This consensus report strongly recommends the implementation of FMT centres for the treatment of C. difficile infection as well as traces the guidelines of technicality, regulatory, administrative and laboratory requirements.
- Published
- 2017
233. Mono, Dual and Triple Moxifloxacin-based Regimens for Helicobacter pylori Eradication
- Author
-
Caro, S. Di, Ojetti, V., Zocco, M.A., Cremonini, F., Bartolozzi, F., Armuzzi, A., Gabrielli, M., Candelli, M., Sanz-Torre, E., Nista, E., Lupascu, A., Cammarota, G., Gasbarrini, G., and Gasbarrini, A.
- Subjects
Research ,Gastrointestinal diseases -- Research - Abstract
[15/39] Mono, Dual and Triple Moxifloxacin-based Regimens for Helicobacter pylori Eradication Purpose: Levofloxacin-based triple regimen has been recently shown to be very effective in H. pylori eradication (>80%). Moxifloxacin is [...]
- Published
- 2001
234. Efficacy of 5, 7 and 10 Days Levofloxacin-based Dual Therapy for H. pylori Eradication
- Author
-
Caro, S. Di, Zocco, M.A., Cremonini, F., Armuzzi, A., Santarelli, L., Candelli, M., Carloni, E., Nista, E., Lupascu, A., Gasbarrini, G., and Gasbarrini, A.
- Subjects
Research ,Gastrointestinal diseases -- Research ,Helicobacter pylori -- Research - Abstract
Efficacy of 5, 7 and 10 Days Levofloxacin-based Dual Therapy for H. pylori Eradication Purpose: In a previous study a 7 days rabeprazole/levofloxacin/ amoxycillin or tinidazole-based triple therapy achieved a [...]
- Published
- 2001
235. Comparison of Different Probiotic Supplementations for Preventing Side Effects of a Standard anti-H. pylori Scheme: A Randomized, Double-blind, Placebo-controlled Study
- Author
-
Cremonini, F., Caro, S. Di, Armuzzi, A., Gabrielli, M., Candelli, M., Nista, E., Lupascu, A., Rapaccini, G., Gasbarrini, G., and Gasbarrini, A.
- Subjects
Research ,Gastrointestinal diseases -- Research - Abstract
F. Cremonini [1] S. Di Caro [2] A. Armuzzi [2] M. Gabrielli [2] M. Candelli [2] E. Nista [2] A. Lupascu [2] G. Rapaccini [2] G. Gasbarrini [2] A. Gasbarrini [...]
- Published
- 2001
236. Helicobacter pylori Cag-a Positive Cytotoxic Strains: A Role in Ischemic Stroke?
- Author
-
Gabrielli, M., Cicconi, V., Bartolozzi, F., Candelli, M., Grillo, R.L., Cremonini, F., Santarelli, L., Tondi, P., Santoliquido, A., Pola, P., Gasbarrini, G., and Gasbarrini, A.
- Subjects
Research ,Gastrointestinal diseases -- Research - Abstract
[13/07] Helicobacter pylori Cag-a Positive Cytotoxic Strains: A Role in Ischemic Stroke? Background and Purpose: Recent studies have reported an association between infection by CagA-positive cytotoxic strains of Helicobacter pylori [...]
- Published
- 2001
237. Cross-Reactivity between anti-CagA Antibodies and Vascular Antigens
- Author
-
Franceschi, F., Sepulveda, A.R., Gasbarrini, A., Gasbarrini, G., Graham, D.Y., and Genta, R.M.
- Subjects
Research ,Gastrointestinal diseases -- Research - Abstract
F. Franceschi [1] A.R. Sepulveda [2] A. Gasbarrini [3] G. Gasbarrini [3] D.Y. Graham [1] R.M. Genta [1] [13/05] [*] Cross-Reactivity between anti-CagA Antibodies and Vascular Antigens Objective: Several studies [...]
- Published
- 2001
238. Helicobacter pylori Eradication in Low Grade Malt Lymphoma: A Systematic Review
- Author
-
Cremonini, F., Bartolozzi, F., Caro, S. Di, Gabrielli, M., Candelli, M., Nista, E.C., Lupascu, A., Rapaccini, G., Gasbarrini, G., and Gasbarrini, A.
- Subjects
Research ,Gastrointestinal diseases -- Research - Abstract
[10/06] Helicobacter pylori Eradication in Low Grade Malt Lymphoma: A Systematic Review Background & Aim: H. pylori eradication is deemed essential for the regression of low-grade MALT of the stomach, [...]
- Published
- 2001
239. Helicobacter pylori CagA positive Strains determine Oxidative DNA Damage in Gastric Cells
- Author
-
Papa, A., Danese, S., Sgambato, A., Ardito, R., Grillo, A., Piscaglia, A., Lupascu, A., Rinelli, A., Vecchio, F., Cittadini, A., Gasbarrini, G., and Gasbarrini, A
- Subjects
Research ,Gastrointestinal diseases -- Research ,Helicobacter pylori -- Research ,Helicobacter infections -- Research - Abstract
A. Papa [1] S. Danese [1] A. Sgambato [2] R. Ardito [2] A. Grillo [1] A. Piscaglia [1] A. Lupascu [1] A. Rinelli [3] F. Vecchio [3] A. Cittadini [2] [...]
- Published
- 2001
240. Gastroduodenal Ultrasonographic Signs and Helicobacter pylori Infection in unselected Dyspepsia
- Author
-
Pretolani, S., Arienti, V., Baigorria, R., Caro, S. Di, Gasbarrini, A., and Gasbarrini, G.
- Subjects
Research ,Gastrointestinal diseases -- Research ,Helicobacter pylori -- Research ,Helicobacter infections -- Research - Abstract
S. Pretolaniti [1] V. Arienti [1] R. Baigorria [1] S. Di Caro [2] A. Gasbarrini [2] G. Gasbarrini [2] [5/06] Gastroduodenal Ultrasonographic Signs and Helicobacter pylori Infection in unselected Dyspepsia [...]
- Published
- 2001
241. Transdifferentiation of Stem Cells in Pancreatic Cells: State of the Art
- Author
-
Di Gioacchino, G., Di Campli, C., Zocco, M.A., Piscaglia, A.C., Novi, M., Santoro, M., Santoliquido, A., Flore, R., Tondi, P., Pola, P., Gasbarrini, G., and Gasbarrini, A.
- Published
- 2005
- Full Text
- View/download PDF
242. Patologie alcol-relate e trattamento dell’alcolismo
- Author
-
Addolorato G, Ferulli A, Cardone S, Leggio L, Gasbarrini G., Gruppo di Studio per le Patologie Alcol relate e. Trattamento Farmacologico dell’Alcolismo (Abenavoli L, Vonghia L, D’Angelo C, Mirijello A, Leso V, Nesci A, Piano A, Capristo E, Malandrino N, Lorenzini F, Del Re A, CAPUTO, FABIO, BERNARDI, MAURO, PARODI E, DE LORENZO A., Addolorato G, Ferulli A, Cardone S, Leggio L, Gasbarrini G & Gruppo di Studio per le Patologie Alcol-relate e Trattamento Farmacologico dell’Alcolismo (Abenavoli L, Vonghia L, D’Angelo C, Mirijello A, Leso V, Nesci A, Piano A, Capristo E, Malandrino N, Caputo F, Lorenzini F, Del Re A, and Bernardi M.
- Subjects
SINDROME DA ASTINENZA DA ALCOL ,TRATTAMENTO DELL'ALCOLISMO ,ALCOLISMO ,EPATOPATIA ALCOLICA ,CARDIOMIOPATIA ALCOLICA - Abstract
L’abuso cronico di alcol rappresenta un problema sociale ed una patologia relativamente frequente nei Paesi occidentali. L’uso inadeguato di alcol rappresenta la causa di circa il 4% di tutte le patologie. Tra le patologie alcol-correlate, l’alcol-dipendenza (altresì definita alcolismo) costituisce il problema più severo ed interessa approssimativamente il 14% della popolazione generale. Ma tale percentuale tende a salire se si considerano anche altre forme di consumo patologico di alcol, quali l’abuso alcolico ed il fenomeno sempre più frequente dello heavy drinking. L’Italia rimane una delle Nazioni ad alto consumo di bevande alcoliche e si stima che l’abuso possa interessare 5 milioni di persone, valutabile attorno ai 4 milioni di individui, definiti come “bevitori eccessivi” e che di questi circa 1 milione sono identificabili come “alcoldipendenti”. La mortalità alcol-correlata, che comprende, oltre alla mortalità per patologie croniche degenerative e neoplastiche, anche la quota derivante da incidenti stradali, omicidi e suicidi, viene quantificata in Italia in circa 30.000 ecessi/anno; inoltre è lecito avanzare l’ipotesi che si tratti di una sottostima se si considera che una notevole quota di cause, con particolare riferimento alle malattie neoplastiche, sfugge alla correlazione con l’abuso etilico.
- Published
- 2009
243. Outcomes of Patients Hospitalized with Community-Acquired, Health Care-Associated, and Hospital-Acquired Pneumonia
- Author
-
Venditti, M, Falcone, M, Corrao,S, Licata, G, Serra, P, Study Group of the Italian Society of Internal Medicine, Salerno, F, Filetti, S, D’Erasmo, E, Rossi Fanelli, F, Cricco, L, Gasbarrone, L, Serafini, C, Ghio, R, Zoppoli, G, Cortellaro, M, Magenta, M, Nuti, R, Valenti, R, Milano, V, Brandimarte, C, Carfagna, P, Di Sciacca, R, Tuttolomondo, A, Serra, MG, Bernardi, M, Li Bassi, S, Stanghellini, V, Boschi, E, Antonaci, S, Vella, F, Catalano, A, Zeneroli, ML, Ascari, E, Veggetti, A, Manfredini, R, Gamberoni, S, Guarnieri, G, Fioretto, A, Di Michele, D, Parisi, D, Liberato, NL, Ronchi, E, Sturbini, S, Canafoglia, P, Gallerani, M, Boari, B, Nielsen, I, Rossetti, A, Bernasconi, M, Giannatempo, C, Turconi, R, Colombo, M, Cappelli, R. Guidi, V, Tassara, R, De Melis, D, Cosentini, R, Arioli, M, Gobbo, G, Presotto, F, Gallana, S, Balduini, C, Bertolino, G, Fera, G, Corazza, RG, Capriglione, I, Pilerio, G, Cappellini, MD, Fabio, G, Carrabba, M, Wu, SC, Secchi, MB, Leone, M, De Feudis, L, Gunelli, M, Ferri, O, Doroldi, C, Pistis, R, Sabbadini, MG, Tresoldi, M, Tedeschi, A, Rossio, R, Lambelet, P, Fascetti, S, Vanoli, M, Casella, G, Agabiti Rosei, E, Salvi, A, Noto, A, Perciaccante, A, Santini, C, Galie`, M, Gasbarrini, G, Grieco, A, Nardi, B, Baritussio, AG, Vannuccini, R, Cappelletti, M, Gentiloni Silveri, N, Lechi, A, Montesi, G., ANNONI, GIORGIO, Venditti, M, Falcone, M, Corrao, S, Licata, G, Serra, P, Study Group of the Italian Society of Internal, M, Salerno, F, Filetti, S, D’Erasmo, E, Rossi Fanelli, F, Cricco, L, Gasbarrone, L, Serafini, C, Ghio, R, Zoppoli, G, Cortellaro, M, Magenta, M, Nuti, R, Valenti, R, Milano, V, Brandimarte, C, Carfagna, P, Di Sciacca, R, Tuttolomondo, A, Serra, M, Bernardi, M, Li Bassi, S, Stanghellini, V, Boschi, E, Antonaci, S, Vella, F, Catalano, A, Zeneroli, M, Ascari, E, Veggetti, A, Manfredini, R, Gamberoni, S, Guarnieri, G, Fioretto, A, Di Michele, D, Parisi, D, Liberato, N, Ronchi, E, Sturbini, S, Canafoglia, P, Gallerani, M, Boari, B, Nielsen, I, Annoni, G, Rossetti, A, Bernasconi, M, Giannatempo, C, Turconi, R, Colombo, M, Cappelli, R., G, V, Tassara, R, De Melis, D, Cosentini, R, Arioli, M, Gobbo, G, Presotto, F, Gallana, S, Balduini, C, Bertolino, G, Fera, G, Corazza, R, Capriglione, I, Pilerio, G, Cappellini, M, Fabio, G, Carrabba, M, Wu, S, Secchi, M, Leone, M, De Feudis, L, Gunelli, M, Ferri, O, Doroldi, C, Pistis, R, Sabbadini, M, Tresoldi, M, Tedeschi, A, Rossio, R, Lambelet, P, Fascetti, S, Vanoli, M, Casella, G, Agabiti Rosei, E, Salvi, A, Noto, A, Perciaccante, A, Santini, C, Galie`, M, Gasbarrini, G, Grieco, A, Nardi, B, Baritussio, A, Vannuccini, R, Cappelletti, M, Gentiloni Silveri, N, Lechi, A, and Montesi, G
- Subjects
MED/09 - MEDICINA INTERNA ,Acquired Pneumonia, Patients outcomes - Abstract
Background: Traditionally, pneumonia has been classified as either community- or hospital-acquired. Although only limited data are available, health care–associated pneumonia has been recently proposed as a new category of respiratory infection. “Health care–associated pneumonia” refers to pneumonia in patients who have recently been hospitalized, had hemodialysis, or received intravenous chemotherapy or reside in a nursing home or long-term care facility. Objective: To ascertain the epidemiology and outcome of community-acquired, health care–associated, and hospital-acquired pneumonia in adults hospitalized in internal medicine wards. Design: Multicenter, prospective observational study. Setting: 55 hospitals in Italy comprising 1941 beds. Patients: 362 patients hospitalized with pneumonia during two 1-week surveillance periods. Measurements: Cases of radiologically and clinically assessed pneumonia were classified as community-acquired, health care–associated, or hospital-acquired and rates were compared. Results: Of the 362 patients, 61.6% had community-acquired pneumonia, 24.9% had health care–associated pneumonia, and 13.5% had hospital-acquired pneumonia. Patients with health care–associated pneumonia had higher mean Sequential Organ Failure Assessment scores than did those with community-acquired pneumonia (3.0 vs. 2.0), were more frequently malnourished (11.1% vs. 4.5%, and had more frequent bilateral (34.4% vs. 19.7%) and multilobar (27.8% vs. 21.5%) involvement on a chest radiograph. Patients with health care–associated pneumonia also had higher fatality rates (17.8% [CI, 10.6% to 24.9%] vs. 6.7% [CI, 2.9% to 10.5%]) and longer mean hospital stay (18.7 days [CI, 15.9 to 21.5 days] vs. 14.7 days [CI, 13.4 to 15.9 days]). Logistic regression analysis revealed that depression of consciousness (odds ratio [OR], 3.2 [CI, 1.06 to 9.8]), leukopenia (OR, 6.2 [CI, 1.01 to 37.6]), and receipt of empirical antibiotic therapy not recommended by international guidelines (OR, 6.4 [CI, 2.3 to 17.6]) were independently associated with increased intrahospital mortality. Limitations: The number of patients with health care–associated pneumonia was relatively small. Microbiological investigations were not always homogeneous. The study included only patients with pneumonia that required hospitalization; results may not apply to patients treated as outpatients. Conclusion: Health care–associated pneumonia should be considered a distinct subset of pneumonia associated with more severe disease, longer hospital stay, and higher mortality rates. Physicians should differentiate between patients with health care–associated pneumonia and those with community-acquired pneumonia and provide more appropriate initial antibiotic therapy.
- Published
- 2009
244. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence.
- Author
-
Pompili, M, Mirante, V, Rondinara, G, Fassati, L, Piscaglia, F, Agnes, S, Covino, M, Ravaioli, M, Fagiuoli, S, Gasbarrini, G, Rapaccini, G, Pompili M, Mirante VG, Rondinara G, Fassati LR, Piscaglia F, Agnes S, Covino M, Ravaioli M, Fagiuoli S, Gasbarrini G, Rapaccini GL., Pompili, M, Mirante, V, Rondinara, G, Fassati, L, Piscaglia, F, Agnes, S, Covino, M, Ravaioli, M, Fagiuoli, S, Gasbarrini, G, Rapaccini, G, Pompili M, Mirante VG, Rondinara G, Fassati LR, Piscaglia F, Agnes S, Covino M, Ravaioli M, Fagiuoli S, Gasbarrini G, and Rapaccini GL.
- Abstract
Aims of this retrospective study were to analyze the efficacy and safety of percutaneous ethanol injection (PEI) and radiofrequency ablation (RFA) in cirrhotic patients with hepatocellular carcinoma (HCC) submitted to orthotopic liver transplantation (OLT). We studied 40 patients undergoing OLT in whom 46 HCC nodules had been treated with PEI (13 nodules), RFA (30 nodules), or PEI+RFA (3 nodules). Child-Turcotte-Pugh class was A in 18 cases, B in 18, and C in 4. The mean waiting time for OLT was 9.5 months. The effectiveness of ablation techniques was evaluated by histological examination of the explanted livers. Complete necrosis was found in 19 nodules (41.3%), partial or absent necrosis in 27 nodules (58.7%). Among the 30 nodules treated by RFA, 14 were completely necrotic (46.7%) and 16 demonstrated partial necrosis (53.3%). Considering the 13 neoplasms undergoing PEI, 3 nodules showed complete necrosis (23.1%), 6 partial necrosis (46.1%), and 4 absent necrosis (30.8%). The rate of complete necrosis was 53.1% for nodules smaller than 3 cm and 14.3% for larger lesions (P = 0.033) but increased to 61.9% when considering only the lesions smaller than 3 cm treated by RFA. During the follow up, HCC recurred in 3 patients treated by PEI. No cases of HCC recurrence at the abdominal wall level were recorded. Percutaneous ablation procedures are effective treatments in cirrhotic patients with HCC submitted to OLT and are not associated to an increased risk of tumor recurrence. RFA provides complete necrosis in most nodules smaller than 3 cm, and appears to be the best treatment option in these cases.
- Published
- 2005
245. A case of posterior reversible encephalopathy syndrome (P.R.E.S.)
- Author
-
Merra, G., Dal Lago, A., Natale, L., Gaetani, E., Caricato, A., Cianfoni, A., Pola, P., Gasbarrini, G., Gasbarrini, A., and Ghirlanda, G.
- Subjects
Blindness ,Seizures (Medicine) ,Encephalopathy ,Health - Abstract
Posterior reversible encephalopathy syndrome is a proposed cliniconeuroradiological entity characterized by several symptoms of different aetiologies. The most important symptoms are headache, confusion, seizures, cortical visual disturbances or blindness, etc. There are three theories for PRES. The aetiology of PRES in this patient remains unclear but it may be related to a pharmacotoxic cause (abuse of drugs) because symptoms including altered mental function, visual loss, stupor and seizures are specific of acute encephalopathy based on treatment with immunosuppressive drugs. The syndrome should be promptly recognized, since it is reversible and readily treated by controlling blood pressure and, based on our experience, decreasing the dose of NSAIDs and eliminating the use of drugs, such as those used by our patient. Keywords: multifactorial syndrome | encephalopathy | pharmacotoxic cause | headache | drugs, Introduction Posterior reversible encephalopathy syndrome is a proposed cliniconeuroradiological entity characterized by several symptoms of different aetiologies (2, 3). The most important symptoms are headache, confusion, seizures, cortical visual disturbances [...]
- Published
- 2009
246. Effect of a gluten-free diet on the risk of enteropathy-associated T-cell lymphoma in celiac disease
- Author
-
Silano, Marco, Volta, Umberto, Vincenzi, Alessandro De, Dessì, Mariarita, Vincenzi, Massimo De, Gasbarrini, G., De Vitis, V., Santini, D., F. , Scaggiante M., Vincenzi, M., Federici, Null, Castellano, E., Calvi, A., Grosso, S., Campanella, J., Corazza, G. R., Sandri, G., Giorgetti, G., Volta, U., Parisi, C., Lo Perfido, S., Perri, F., Festa, V., Pelli, M. A., Cavalletti, M. L., Segato, S., Curzio, M., Pennazio, M., Rossini, F. P., Picarelli, A., Pera, A., Ercole, E., Passaleva, M. T., Barbato, M., Usai, P., Dore, M. F., Chilovi, F., Piazzi, L., Zancanella, L., Boarino, V., Ferrari, A., GRECO, LUIGI, AURICCHIO, SALVATORE, Silano, Marco, Volta, Umberto, Vincenzi, Alessandro De, Dessì, Mariarita, Vincenzi, Massimo De, Gasbarrini, G., De Vitis, V., Greco, Luigi, Auricchio, Salvatore, Santini, D., F., Scaggiante M., Vincenzi, M., Federici, Null, Castellano, E., Calvi, A., Grosso, S., Campanella, J., Corazza, G. R., Sandri, G., Giorgetti, G., Volta, U., Parisi, C., Lo Perfido, S., Perri, F., Festa, V., Pelli, M. A., Cavalletti, M. L., Segato, S., Curzio, M., Pennazio, M., Rossini, F. P., Picarelli, A., Pera, A., Ercole, E., Passaleva, M. T., Barbato, M., Usai, P., Dore, M. F., Chilovi, F., Piazzi, L., Zancanella, L., Boarino, V., and Ferrari, A.
- Subjects
Male ,Time Factors ,Lymphoma ,Physiology ,Gastroenterology ,Coeliac disease ,Celiac disease, Enteropathy-associated T-cell lymphoma, Gluten-free diet ,Child ,chemistry.chemical_classification ,Settore BIO/12 ,Middle Aged ,Child, Preschool ,Gluten-free diet ,Enteropathy-associated T-cell lymphoma ,Female ,Human ,Adult ,medicine.medical_specialty ,Intestinal Neoplasm ,Glutens ,Adolescent ,Time Factor ,Diet therapy ,Malignancy ,Lymphoma, T-Cell ,Follow-Up Studie ,Celiac disease ,Celiac Disease ,Follow-Up Studies ,Humans ,Infant ,Intestinal Neoplasms ,Patient Compliance ,Stomach Neoplasms ,Stomach Neoplasm ,Internal medicine ,medicine ,Risk factor ,Preschool ,business.industry ,nutritional and metabolic diseases ,medicine.disease ,T-Cell ,Gluten ,digestive system diseases ,chemistry ,Gluten free ,business - Abstract
Patients with celiac disease have an increased rate of enteropathy-associated T-cell lymphoma, but conflicting data are available about the protective role of a gluten-free diet with regard to the development of this malignancy. We followed 1,757 celiac patients for a total period of 31,801 person-years, collecting data about the frequency of gluten intake and the incidence of the enteropathy-associated T-cell lymphoma. Out of the nine celiac patients who developed an intestinal lymphoma [standard morbidity ratio of 6.42 (95% CI = 2.9-12.2; P < 0.001)], only two kept a strict gluten-free diet after the diagnosis of celiac disease and developed the malignancy after the peridiagnosis period of 3 years, dropping therefore the standard morbidity ratio to 0.22 (95%CI = 0.02-0.88; P < 0.001). The risk of developing an intestinal lymphoma for the celiac patients that used to have dietary gluten was significant (X(2 )= 4.8 P = 0.01). These results show that a strict gluten-free diet is protective towards the development of enteropathy-associated T-cell lymphoma.
- Published
- 2008
247. Delayed diagnosis of coeliac disease increases cancer risk
- Author
-
Silano, Marco, Volta, Umberto, Mecchia, Anna, Dessì, Mariarita, Di Benedetto, Rita, De Vincenzi, Massimo, Gasbarrini, G., De Vitis, D., Greco, L., Auricchio, S., Santini, D., Scaggiante, F., Federici, M. D., Castellano, E., Sategna-Guidetti, Null, Grosso, S., Campanella, J., Corazza, G. R., Sandri, G., Giorgetti, G., Amici, Monica, De Franceschi, L., Lo Perfido, S., Perri, F., Festa, V., Pelli, M. A., Cavalletti, M. L., Segato, S., Curzio, M., Pennazio, M., Rossini, F. P., Picarelli, A., Pera, A., Ercole, E., Passaleva, M. T., Barbato, M., Usai, P., Dore, M. F., Chilovi, F., Piazzi, L., Zancanella, L., Boarino, V., Ferrari, A., Silano, Marco, Volta, Umberto, Mecchia, Anna, Dessì, Mariarita, Di Benedetto, Rita, De Vincenzi, Massimo, Gasbarrini, G., De Vitis, D., Greco, Luigi, Auricchio, Salvatore, Santini, D., Scaggiante, F., Federici, M. D., Castellano, E., Sategna Guidetti, Null, Grosso, S., Campanella, J., Corazza, G. R., Sandri, G., Giorgetti, G., Amici, Monica, De Franceschi, L., Lo Perfido, S., Perri, F., Festa, V., Pelli, M. A., Cavalletti, M. L., Segato, S., Curzio, M., Pennazio, M., Rossini, F. P., Picarelli, A., Pera, A., Ercole, E., Passaleva, M. T., Barbato, M., Usai, P., Dore, M. F., Chilovi, F., Piazzi, L., Zancanella, L., Boarino, V., and Ferrari, A.
- Subjects
Registrie ,tumors ,Adult ,Male ,Risk ,medicine.medical_specialty ,Time Factors ,Time Factor ,Delayed diagnosis ,Gastroenterology ,Coeliac disease ,Internal medicine ,Neoplasms ,medicine ,Neoplasm ,Humans ,Age Factor ,In patient ,Registries ,lcsh:RC799-869 ,Coeliac disease, neoplasm, tumors ,Age Factors ,Celiac Disease ,Female ,Middle Aged ,business.industry ,Medicine (all) ,Settore BIO/12 ,Cancer ,General Medicine ,Hepatology ,medicine.disease ,Population study ,lcsh:Diseases of the digestive system. Gastroenterology ,Cancer risk ,business ,neoplasm ,Human ,Research Article - Abstract
Background The association between coeliac disease (CD) and neoplasms has been long established, but few data are available about the risk factors. The aim of this paper is to estimate the risk of developing a neoplasm among non diagnosed coeliac patients and to evaluate if this risk correlates with the age of patients at diagnosis of coeliac disease. Methods The study population consists of patients (n = 1968) diagnosed with CD at 20 Italian gastroenterology referral Centers between 1st January 1982 and 31st March 2005. Results The SIR for all cancers resulted to be 1.3; 95% CI = 1.0–1.7 p < 0.001. The specific SIRs for non Hodgkin lymphoma was 4.7; 95% CI = 2.9–7.3 p < 0.001, for the small bowel carcinoma 25; 95% CI = 8.5–51.4 p < 0.001, for non Hodgkin lymphoma 10; 95% CI = 2.7–25 p = 0.01, finally for the stomach carcinoma 3; 95% CI = 1.3–4.9 p < 0.08. The mean age at diagnosis of CD of patients that developed sooner or later a neoplasm was 47,6 ± 10.2 years versus 28.6 ± 18.2 years of patients who did not. Conclusion Coeliac patients have an increased risk of developing cancer in relation to the age of diagnosis of CD. This risk results higher for malignancies of the gastro-intestinal sites. An accurate screening for tumors should be performed in patients diagnosed with CD in adulthood and in advancing age.
- Published
- 2007
248. Neuroendocrine and psychological assessment in a guinness 10 days scuba dive
- Author
-
Revelli, L., Addolorato, Giovanni, D'Amore, A., Carrozza, C., Giubileo, G., Puiu, A., Lombardi, C. P., Bellantone, R., Gasbarrini, G., Leggio, Lorenzo, Mirijello, Antonio, D'Angelo, Cristina, Ferrulli, Anna, Vonghia, Luisa, Cardone, Silvia, Leso, Veruscka, Abenavoli, Ludovico, Raffaelli, Marco, De Crea, Carmela, Princi, Pietro, Spaventa, Antonio, Sessa, Luca, Rota, Carlo, Costanzo, Corrado, Revelli, L., Addolorato, Giovanni, D'Amore, A., Carrozza, C., Giubileo, G., Puiu, A., Lombardi, C. P., Bellantone, R., Gasbarrini, G., Leggio, Lorenzo, Mirijello, Antonio, D'Angelo, Cristina, Ferrulli, Anna, Vonghia, Luisa, Cardone, Silvia, Leso, Veruscka, Abenavoli, Ludovico, Raffaelli, Marco, De Crea, Carmela, Princi, Pietro, Spaventa, Antonio, Sessa, Luca, Rota, Carlo, and Costanzo, Corrado
- Subjects
Adult ,Male ,medicine.medical_specialty ,Breath Test ,Self-Assessment ,Psychometrics ,Depression scale ,Stre ,Diving ,Physical Therapy, Sports Therapy and Rehabilitation ,Anxiety ,Task Performance and Analysi ,Cortisol ,Task Performance and Analysis ,Humans ,Medicine ,Psychological testing ,Orthopedics and Sports Medicine ,Psychiatry ,Depression (differential diagnoses) ,Spectrum Analysi ,Sport ,business.industry ,Depression ,Spectrum Analysis ,Panic symptoms ,Environmental exposure ,Environmental Exposure ,Neurosecretory Systems ,Breath Tests ,Italy ,Physical therapy ,Neurosecretory System ,Female ,medicine.symptom ,business ,human activities ,Scuba diver ,Psychometric ,Sports ,Psychopathology ,Human - Abstract
This study was designed to evaluate physiological and psychological stress parameters in 2 professional trained scuba divers, using a unique physiopathologic model, offered by the guinness 240 hours scuba dive. Two scuba dive masters have spent 240 hours at 6 - 8 meters depth (26.4 ft) in Ponza Island water (Italy). Blood samples were collected daily in the underwater bell; samples were carried out of water in waterproof bags. Breath samples were collected, measuring ethylene release. Psychological assessment was performed using the State and Trait Anxiety Inventory and the Zung self-rating depression scale. In the studied subjects, cortisol and prolactin showed physiological pulsatile secretion. Breath ethylene didn't exceed normal values. At the start of the study, no subjects showed high levels of state anxiety, trait anxiety and current depression. Psychometric scales scores remained steady during the diving period and no subjects showed anxiety and/or depression and/or panic symptoms during the time of observation. The present study shows that, although the long-time diving, well trained professional divers did not develop anxiety and/or depression. No subject discontinued the diving due to occurred psychological disorders or systemic events. The present report shows that the long-term diving permanence is possible, at least in well trained scuba divers.
- Published
- 2007
249. Role of Helicobacter pylori CagA+ infection in determining oxidative DNA damage in gastric mucosa
- Author
-
Gasbarrini, Antonio, Papa, Alfredo, Danese, S, Sgambato, Alessandro, Ardito, R, Zannoni, Gian Franco, Rinelli, A, Vecchio, Fm, Gentiloni Silveri, N, Cittadini, A, Gasbarrini, G., Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Papa A (ORCID:0000-0002-4186-7298), Danese S, Sgambato, Alessandro (ORCID:0000-0002-9487-4563), Ardito R, Zannoni G (ORCID:0000-0003-1809-129X), Rinelli A, Vecchio Fm, Gentiloni Silveri N, Cittadini A, Gasbarrini G., Gasbarrini, Antonio, Papa, Alfredo, Danese, S, Sgambato, Alessandro, Ardito, R, Zannoni, Gian Franco, Rinelli, A, Vecchio, Fm, Gentiloni Silveri, N, Cittadini, A, Gasbarrini, G., Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Papa A (ORCID:0000-0002-4186-7298), Danese S, Sgambato, Alessandro (ORCID:0000-0002-9487-4563), Ardito R, Zannoni G (ORCID:0000-0003-1809-129X), Rinelli A, Vecchio Fm, Gentiloni Silveri N, Cittadini A, and Gasbarrini G.
- Abstract
BACKGROUND: Although Helicobacter pylori is a risk factor for gastric cancer, the role of the bacterium in the development of this malignancy is not defined precisely. Reactive oxygen species (ROS) could play an important role in carcinogenesis by inducing DNA damage. The aims of the present study were: 1) to assess the production of ROS and 8-hydroxy-2'-deoxyguanosine (8-OHdG), a sensitive marker of oxidative DNA injury, in gastric mucosa, according to H. pylori status and cytotoxic associated gene product A (CagA); 2) to determine the relationship between ROS generation and amount of 8-OHdG. METHODS: Gastric biopsy specimens were obtained from 60 consecutive patients. ROS generation was measured by luminol enhanced chemiluminescence. 8-OHdG detection was performed by an immunoperoxidase method, using a specific anti 8-OHdG monoclonal antibody. RESULTS: 40/60 patients (67%) were H. pylori-positive. ROS generation was significantly higher in patients positive for H. pylori infection as compared to negative. 8-OHdG detection was performed in 30 patients in which CagA presence was also investigated. High expression of 8-OHdG was detected in 14/20 (70%) H. pylori-positive patients (13 CagA+ and 1 CagA-) and in 2/10 (20%) H. pylori-negative patients. A significant correlation was found between ROS production and 8-OHdG content. CONCLUSION: H. pylori infection by a CagA+ strain is associated with the highest production of ROS to which a severe oxidative DNA damage corresponds. This sequence of events could support the hypothesis that the oxygen-free radicals-mediated damage due to H. pylori cytotoxic strains could be a driving force that leads from chronic gastritis to gastric carcinoma.
- Published
- 2002
250. High rate of helicobacter pylori re-infection in patients affected by type 1 diabetes
- Author
-
Gasbarrini, Antonio, Ojetti, V, Pitocco, D, Bartolozzi, F, Danese, S, Migneco, A, Lupascu, A, Pola, P, Ghirlanda, G, Gasbarrini, G., Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Ojetti V, Pitocco D (ORCID:0000-0002-6220-686X), Bartolozzi F, Danese S, Migneco A, Lupascu A, Pola P, Ghirlanda G, Gasbarrini G., Gasbarrini, Antonio, Ojetti, V, Pitocco, D, Bartolozzi, F, Danese, S, Migneco, A, Lupascu, A, Pola, P, Ghirlanda, G, Gasbarrini, G., Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Ojetti V, Pitocco D (ORCID:0000-0002-6220-686X), Bartolozzi F, Danese S, Migneco A, Lupascu A, Pola P, Ghirlanda G, and Gasbarrini G.
- Abstract
N/A
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.